2 mL Exacta-Med Oral Dispenser
Baxa Corp (Englewood, Colo) recently
introduced the 2 mL Exacta-Med Oral
Dispenser. The company's line of oral liquid
medication dispensers is available in
sizes from 0.5 mL to 60 mL. The addition
of the 2-mL dispenser provides health
professionals with the flexibility and
convenience to meet the full range of
their oral dosing needs. Exacta-Med
Oral Dispensers play a vital role in preventing
wrong-route administration of
nonintravenous (IV) fluid drugs. The
unique dispenser tip cannot connect to
a Luer needle hub, needleless connector,
or patient IV access device. Designed
to ensure dose accuracy while
preventing medication errors and
wrong-route administration of IV drugs,
oral dispensers and accessories are recommended
by the Institute for Safe
Medication Practices for use in oral and
enteral fluid drug delivery. For more
information call 800-567-BAXA (800-567-2292), or visit www.baxa.com.
Ampicillin and Sulbactam for Injection
Abraxis Pharmaceutical Products
(Schaumburg, Ill) recently received FDA
approval for its abbreviated new drug
application for the combination drug
ampicillin and sulbactam for injection
15 g pharmacy bulk pack. The product is
AP-rated, latex-free, and the generic
equivalent of Pfizer Inc's Unasyn.
Ampicillin and sulbactam is an
injectable antibacterial combination
consisting of the semisynthetic antibiotic
ampicillin sodium and the beta-lactamase
inhibitor sulbactam sodium.
Administered intravenously or intramuscularly,
the product is indicated for
the treatment of several skin and skin
structure, intra-abdominal, and gynecological
infections due to susceptible
strains of microorganisms. The product
is also available in 1.5-g and 3-g single-dose
vials. For more information call 800-551-7176, or visit www.appdrugs.com.
Lorazepam Injection
Bedford Laboratories (Bedford,
Ohio), a division of Ben Venue
Laboratories Inc, has begun shipping
lorazepam injection. The product is AP-rated
to Baxter Healthcare Corp's Ativan
Injection. Lorazepam injection is indicated
for the treatment of status epilepticus.
The product is also indicated in
adult patients for preanesthetic medication,
producing sedation (sleepiness or
drowsiness), relief of anxiety, and a
decreased ability to recall events related
to the day of surgery. Lorazepam injection
is most useful in those patients who
are anxious about their surgical procedure
and who would prefer to have
diminished recall of the events of the
day of surgery. The product is available in
a 2-mg/mL, 1-mL single-dose vial and a
10-mL multiple-dose vial, as well as a 4-mg/mL, 1-mL single-dose vial and a 10-mL multiple-dose vial.
For more information,
visit www.bedfordlabs.com, or call
800-521-5169.
Symbiq
Hospira Inc (Lake Forest, Ill) recently
introduced the Symbiq infusion system,
a medically and technologically advanced
medication management system
that combines ease of use, reliability,
and next-generation technology.
Infusion systems like Symbiq administer
intravenous (IV) medications, fluids,
and solutions to patients. It is critical
for these devices to have safeguards,
such as safety software and instinctive
programming options, to help clinicians
prevent medication errors.
Symbiq is an "intelligent" pump that
incorporates differentiated, clinician-friendly
features to decrease errors
and improve workflow. Symbiq's features
include advanced infusion system
with patient-safety software
already integrated into the device to
assure compliance; sophisticated
reporting capabilities and support of
hospital standardization; intuitive LCD
display—similar to an automated teller
machine screen—that features simple
layouts and touch-activated buttons to
help minimize errors; an easy-to-read
display with large font and color
prompts; quick-release pole clamp
that enables clinicians to rapidly move
or attach the system to an IV pole or
bed rail; and an automatic medication-loading
slot that allows easy and timesaving
insertion of the medication
administration set. For more information,
visit www.hospira.com, or call
877-9HOSPIRA (877-946-7747).
